Institute Of Cardiology & Internal Diseases, Kazakhstan
1 clinical trials · Sponsor
◉ Watch Institute Of Cardiology & Internal Diseases, Kazakhstan
| Record | Firm | Date |
|---|---|---|
| Open-Label Efficacy and Safety Study of the Elbasvir/ Grazoprevir Fixed Dose Combination Patients With Chronic HCV GT1b (NCT03222167) | Institute Of Cardiology & Internal Diseases, Kazakhstan | 2017-10-01 |
Track Institute Of Cardiology & Internal Diseases, Kazakhstan automatically
Every clearance here is in the API, with alerts when new ones post.